These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33721439)

  • 1. Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis.
    Wu J; Wang Z; Jin C; Ren H; Hu Y; Yang B; Hu Y
    J BUON; 2021; 26(1):101-108. PubMed ID: 33721439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour location and efficacy of first-line EGFR inhibitors in
    Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
    ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
    Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
    Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.
    Mineur L; François E; Plassot C; Phelip JM; Miglianico L; Dourthe LM; Bonichon N; Moreau L; Guimbaud R; Smith D; Achille E; Hervé R; Bons JM; Remy S; Faroux R; Villing AL; Mahamat A; Rabbia I; Soulié P; Baumgaertner I; Mathé N; Vazquez L; Boustany R
    PLoS One; 2020; 15(12):e0243997. PubMed ID: 33347495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cetuximab combined with IMRT and concurrent chemotherapy in treating locally advanced nasopharyngeal carcinoma.
    Yang P; Liu J; Yong H; Ma J; Gao X
    J BUON; 2021; 26(1):138-144. PubMed ID: 33721444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
    Rouyer M; François E; Cunha AS; Monnereau A; Noize P; Robinson P; Droz-Perroteau C; Le Monies de Sagazan A; Jové J; Lassalle R; Moore N; Fourrier-Réglat A; Smith D;
    Clin Colorectal Cancer; 2018 Jun; 17(2):129-139. PubMed ID: 29523416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and Prognostic Factors of Cetuximab Therapy in Treating KRAS or All RAS Wild-type Metastatic Colorectal Cancer].
    Wu X; Deng BB; Bai CM; Zhao L; Cheng YJ; Li XY; Li NN; Zhou JF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Oct; 40(5):660-666. PubMed ID: 30404699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
    Gürsoy P; Çakar B; Almuradova E; Karateke M; Doğanavşargil B; Sezak M; Harman M; Karabulut B
    J Chemother; 2021 May; 33(3):180-186. PubMed ID: 33349195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
    Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a High-Throughput Genotyping Platform (OncoMap) for
    Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
    Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
    Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
    Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
    Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
    Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.